[Consideration on molecular imaging technology as a tool for drug research and development].
Molecular imaging technology such as positron emission tomography (PET) and magnetic resonance imaging (MRI) are known as powerful tools for clinical diagnosis in neurology, oncology and so on. As applications to new drug research and development, there are three methodologies which are PK (Pharmacokinetics study), PD (Pharmacodynamic study), and efficacy study. When we use these methodologies for the drug research, we must consider construction of technological environment (tracer, animal model, imaging analysis software, and clinical database) and regulatory environment for GMP (Good Manufacturing Practice) and GCP (Good Clinical Practice) level. Additionally, concept of microdosing and exploratory clinical study was proposed in western countries and the guidance on microdosing study was also announced by Health, Labor and Welfare Ministry on June 3rd 2008. However they may be still in learning phase, we must meet with complexity, high cost, and indigestion. To promote molecular imaging technology into the drug research, integration of the scientists between academia and industry is important because it needs much type of the advanced technologies and skills.
Yajima
Kazuyoshi
K
Bioimaging, Applied Pharmacology Research Laboratories, Astellas Pharma Inc, Ibaraki, Japan. yajima@mprcf.or.jp
Nishimura
Shintaro
S
D000818:Animals; D003952:Diagnostic Imaging; D055808:Drug Discovery / Q000379:methods; D004345:Drug Industry; D006801:Humans; D010599:Pharmacokinetics; D049268:Positron-Emission Tomography; D016896:Treatment Outcome